Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
暂无分享,去创建一个
A. Tefferi | M. Patnaik | T. Lasho | R. Ketterling | C. Finke | N. Gangat | A. Mangaonkar | R. Vallapureddy | Rangit R. Vallapureddy
[1] Yi Zhang,et al. TET-mediated active DNA demethylation: mechanism, function and beyond , 2017, Nature Reviews Genetics.
[2] K. Robertson,et al. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance , 2016, Blood Cancer Journal.
[3] F. Solé,et al. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features , 2016, Oncotarget.
[4] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[5] M. Stratton,et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents , 2016, Nature Communications.
[6] A. Tefferi,et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia , 2015, Blood Cancer Journal.
[7] J. Byrd,et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome , 2015, Nature Communications.
[8] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[9] D. Neuberg,et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.
[10] O. Abdel-Wahab,et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. , 2014, Blood.
[11] E. Solary,et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients , 2014, Leukemia.
[12] Stein Aerts,et al. High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes , 2012, PloS one.
[13] A. Kohlmann,et al. Landscape of TET2 mutations in acute myeloid leukemia , 2012, Leukemia.
[14] Ying Li,et al. TREAT: a bioinformatics tool for variant annotations and visualizations in targeted and exome sequencing data , 2011, Bioinform..
[15] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.